Search

Your search keyword '"Loda, Massimo"' showing total 2,368 results

Search Constraints

Start Over You searched for: Author "Loda, Massimo" Remove constraint Author: "Loda, Massimo"
2,368 results on '"Loda, Massimo"'

Search Results

51. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression 1

52. Supplementary Vignette 2 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology

53. Supplementary Vignette 1 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology

54. Supplementary Vignette 3 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology

55. Supplementary Figure 1 from Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology

56. Supplementary Figure 10 from Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis

57. Genomic correlates of clinical outcome in advanced prostate cancer

59. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer

60. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer

65. The Intersection of Epidemiology and Pathology

66. Introduction to Pathology

67. Introduction to Histology

69. Paired exome analysis of Barrett's esophagus and adenocarcinoma

73. Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

74. Supplementary Table S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

75. Supplementary Methods S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

76. Data from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

77. Supplementary Table 1 from Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study

79. Supplementary Figure 1 from Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study

80. Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis

83. p63 Regulates Commitment to the Prostate Cell Lineage

87. Integration of Multiple Spatial-Omics Modalities Reveals Unique Insights into Molecular Heterogeneity of Prostate Cancer

88. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

89. Germline genetic variants associated with somatic TMPRSS2:ERG fusion status in prostate cancer: a genome-wide association study

90. Linking African ancestral substructure to prostate cancer health disparities

91. Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression

92. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

95. Multiclass Cancer Diagnosis Using Tumor Gene Expression Signatures

Catalog

Books, media, physical & digital resources